ABIVAX
ISIN: FR0012333284 | Ticker: ABVX | LEI: 969500D8TMNB184OJU95
Country: France
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (obefazimod) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
5 Rue de la Baume, 75008 Paris – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 13.11.23 | None | Other | Buy | EUR 39.84 |
| 13.07.23 | None | Other | Sell | EUR 3,101,480.01 |
| 27.03.23 | None | Other | Other | EUR 249,996.50 |
| 27.02.23 | None | Other | Other | EUR 9,977,500.00 |
FR0012333284
LEI969500D8TMNB184OJU95
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.